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Abstract 
Postlaunch monitoring of functional foods can encompass monitoring of effectiveness under 
conditions of customary use. To this end, the effectiveness of phytosterol/-stanol enriched 
margarine consumption in free-living conditions was investigated with data from the Dutch 
“Doetinchem cohort study”. In total, 4505 subjects (aged 26–70 years) were examined in 
1994–1998 and re-examined during 1999–2003. A general and a food frequency 
questionnaire and non-fasting blood samples for total and HDL cholesterol determination 
were obtained. Subjects were stratified into phytosterol/-stanol enriched margarine users 
(n = 84) and non-users (n = 4421) based on the re-examination data, as these margarines 
were available on the Dutch market from 1999 onwards.  
Mean spontaneous daily use (g ± SD) of phytosterol-containing margarine (n = 71) was 15 ± 8 
and of phytostanol-containing margarine (n = 13) 9 ± 6. After five years, total blood 
cholesterol had increased with 0.26 mmol/l in non-users while it had not significantly changed 
in users. The difference in total blood cholesterol change in users versus non-users was 
−0.30 mmol/l (p < 0.001). The beneficial effect of the phytosterol/-stanol enriched margarine, 
used under customary conditions can be characterized as a stabilization of cholesterol levels. 
This is the first report finding a modest beneficial effect on blood cholesterol level under 
customary conditions thereby partly confirming findings from clinical trials.  
1. Introduction 
To our opinion a postlaunch monitoring (PLM) system should not only notify, analyse and 
evaluate potential side effects of a specific food, and investigate consumption patterns, but 
should also perform a risk-benefit analyses in which both the positive and negative health 
effects are weighed on a population level. In order to be able to do so population data on 
effectiveness of foods rather than efficacy data obtained in controlled clinical settings are 
required in addition to customary intake data and data on (un)known adverse effects.  
Serum total cholesterol is a major risk factor for coronary heart diseases. A meta-analysis of 
Law et al. (1994) showed that a long-term reduction in serum total cholesterol of 10% lowers 
the risk of ischemic heart disease by 50% at the age of 40 and by 20% at the age of 70. Thus, 
cholesterol-lowering strategies could result in a substantial health benefit at a population 
level. In many clinical trials, it has been reported that phytosterols or -stanols, when 
consumed over 1 g per day, induce a significant reduction of serum total cholesterol and low-
density lipoprotein (LDL) cholesterol concentration (Law, 2000, Miettinen et al., 1995, 
Weststrate and Meijer, 1998, Hendriks et al., 1999 and Hallikainen et al., 2000). Dosages of 
1.5–3 g phytosterols and -stanols per day were shown to reduce total serum cholesterol by 8–
17% and LDL cholesterol by 9–19% (Amundsen et al., 2002), whereas high-density 
lipoprotein (HDL) cholesterol concentrations remained unaffected. These effects have been 
confirmed in a meta-analysis of 41 trials in which even an additive effect on cholesterol-
lowering drug use was demonstrated (Katan et al., 2003). Without adherence to a controlled 
diet, the consumption of 20 g phytosterol/-stanol enriched margarine has been shown to have 
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a lipid lowering effect (Hendriks et al., 2003 and Geelen et al., 2002) and to augment the LDL 
cholesterol-lowering effect of other cholesterol-lowering strategies (Nestel et al., 2001). These 
results have lead to the market introduction of several phytosterol/-stanol enriched foods. The 
level of evidence of the use of these foods on blood cholesterol lowering is sufficient to meet 
the criteria laid down in the Passclaim consensus report (Aggett et al., 2005). As the foods 
enriched with phytosterol esters are regarded as novel foods extensive safety evaluations 
have been performed prior to market launch, and these have all been published in this journal 
(Lea et al., 2004, Baker et al., 1999, Wolfreys and Hepburn, 2002, Sanders et al., 2000, 
Ayesh et al., 1999, Weststrate et al., 1999, Waalkens-Berendsen et al., 1999 and Hepburn et 
al., 1999). Although phytostanol esters were not subject to the novel foods regulation in 
Europe for formal reasons, also these have gone through safety testing procedures (Slesinski 
et al., 1999, Turnbull et al., 1999a, Turnbull et al., 1999b, Turnbull et al., 1999c and Katan et 
al., 2003). Also some PLM investigations have been done upon request by the EU (SCF, 
2002b and SCF, 2002a). The main focus of these PLM investigations were on consumption 
levels, consumption patterns by target and/or non-target groups, and on consumer 
notifications of side effects. Until now the effects of phytosterol/-stanol enriched foods have 
only been studied with controlled intake of phytosterols or -stanols. To our knowledge, no 
study has been published in which the effect of foods enriched with phytosterols/-stanols on 
blood lipids has been investigated under free-living conditions without a controlled diet. For 
PLM purposes we are interested in the health benefits of the consumption of these type of 
foods in the general target population. We, therefore, investigated the consumption level of 
phytosterol/-stanol enriched margarines under free-living conditions, and the subsequent 
effect on blood cholesterol levels.  
2. Materials and methods 
Data were available from the Dutch Doetinchem cohort study for 4505 subjects (2101 males, 
2320 females, aged 26–70 years) examined in the years 1994–1998 and re-examined at five 
years follow-up during 1999–2003. The main objective of this study is to investigate changes 
in time of risk factors and way of live within the same individuals. Furthermore the relationship 
between changes in way of live and changes in risk factors is studied. Details of this study 
have been published elsewhere (Blokstra et al., 2006). A general questionnaire and a 
validated food frequency questionnaire asking for usual intake in the previous year were filled 
out (Ocké et al., 1997). Participants were able to tick multiple types of bread spreads. For 
each indicated type of bread spread, one or two brandnames of the breadspread used could 
be filled out in an open section (e.g. phytosterol-enriched margarine: Becel pro.activ®; 
phytostanol-enriched margarine: Benecol®). The amount of breadspread used was calculated 
by multiplying the number of slices of bread consumed daily by the amount of spread on a 
slice that was estimated by a series of photographs. At least until 2003 phytosterol/-stanol 
enriched margarines were the main sources of these substances on the Dutch market. Other 
phytosterol/-stanol enriched foods have only been introduced from 2003 onwards. Non-fasting 
blood samples for total and HDL cholesterol determination were obtained using a 
standardised protocol (Houterman et al., 2001).  
Subjects were stratified into phytosterol/-stanol enriched margarine users (n = 84) and non-
users (n = 4421) based on the follow-up data, as these margarines were available on the 
Dutch market from 1999 onwards. For descriptive purposes absolute numbers and 
percentages of general characteristics of the enriched margarine users and non-users were 
calculated. Some of the general characteristics are presented as mean ± SD. Statistical 
differences between the general characteristics of users vs non-users were tested with 2-test 
or a Student’s t test.  
In order to be able to describe the enriched margarine users more thoroughly and to compare 
with cholesterol-lowering medicine users we have divided the population in four groups for 
further analysing: i.e. phytosterol/-stanol enriched margarine users (subjects who used 
enriched margarine but no cholesterol-lowering drugs, n = 72), cholesterol lowering drug 
users (subjects who used cholesterol-lowering drugs but no enriched margarine, n = 218), 
combination users (subjects who used both enriched margarine and cholesterol-lowering 
drugs, n = 12) and total non-users (subjects who used neither enriched margarine or 
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cholesterol-lowering drugs, n = 4205). We compared the general characteristics of these four 
groups, but we only present those characteristics that are statistically different. We do not 
have information on the type of cholesterol-lowering drugs that were used, but in accordance 
to the major trend in affluent countries an increasing majority will use statins.  
Because producers of the phytosterol/-stanol enriched margarines claim that about a 10% 
decline in total blood cholesterol concentration can be achieved by the recommended 
consumption level of these products, we calculated the percentage of subjects that attained a 
decline in total blood cholesterol level of 10%. We also calculated the average amount of 
the enriched margarine consumed daily among the users, and how many of the users took 
the recommended amount of 20 g of margarine per day.  
Effectiveness of usage was analysed through calculating the difference in total blood 
cholesterol change between baseline and re-examination in the four groups. Similarly, we 
calculated the change in HDL cholesterol and the total/HDL cholesterol ratio. These results 
are presented as mean ± SD. The difference in each group was tested with a paired t-test and 
between groups with ANOVA. When a significant difference between groups was detected, a 
Bonferroni test was performed to test which differences were significant while adjusting for 
multiple comparisons.  
Multiple regression analysis was used to analyze the effect of phytosterol/-stanol enriched 
margarine on the observed lipid changes between baseline and re-examination, while 
variables known to influence changes in blood lipid concentrations such as sex, age, alcohol 
intake, fat intake, BMI, smoking behavior, diabetes, the use of cholesterol lowering drugs and 
an interaction term for use of enriched margarine and cholesterol-lowering drugs, were 
entered into the model as covariates. The mean total blood cholesterol ((total blood 
cholesterol at re-examination + baseline total blood cholesterol)/2) was put into the model to 
correct for regression to the mean. To compare the quantitative blood cholesterol change of 
the enriched margarine with that of blood cholesterol-lowering drugs, we also analysed the 
effect of those drugs by multiple regression analysis. The crude as well as the adjusted 
results are presented (ß (95% CI)).  
For all the analyses a significance level of 0.05 was chosen. The data analyses were 
performed using the statistical software package SAS version 9.1.  
3. Results 
No differences were observed between the enriched margarine users and non-users for most 
general characteristics, except for alcohol use, dietary fat intake, baseline total blood 
cholesterol, prevalence of ever being diagnosed with high cholesterol level and cholesterol-
lowering drug use (Table 1). There were more subjects who drank more than two glasses of 
alcohol per day, among enriched margarine users compared to non-users (30% vs. 18%), 
and among the users there were less subjects who had a fat intake greater than 30 en% 
(74% vs. 89%). Users of enriched margarine had a higher baseline total blood cholesterol 
level than non-users (6.2 vs. 5.5 mmol/l). Similarly, among the users there where more 
subjects ever diagnosed with high cholesterol level compared to non-users (56% vs. 17%) 
and more users of enriched margarine used cholesterol-lowering drugs. There were no 
statistically significant differences (p > 0.05) between men and women for baseline values of 
total serum cholesterol (data not shown).  
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Table 1.  
General characteristics of users versus non-users of phytosterol/-stanol enriched margarine in 
a Dutch cohort (n = 4505), 1999–2003  
Characteristic  
 
Users  
 
Non-usersa  
 
p-Valueb  
 
 n = 84 % n = 4421 %  
Gender 
Male 37 44 2101 47 ns 
Female 47 56 2320 53  
      
Age, yrs (mean ± SD) 53.7 ± 8.5  51.2 ± 10.2  ns 
      
Education 
Low 37 44 2210 50 ns 
Middle 20 24 1238 28  
High 27 32 973 22  
      
Subjective health 
Bad 1 1 43 1 ns 
Moderate 9 11 574 13  
Good 74 88 3804 86  
      
Smoking 
Never 28 34 1546 35 ns 
Ex 43 52 1727 39  
Current 12 14 1148 26  
      
Alcohol use 
None 22 26 1501 34 0.018 
1–2 glasses/d 37 44 2126 48  
>2 glasses/d 25 30 794 18  
BMI, kg/m2 (mean ± SD) 26.6 ± 4.1  26.3 ± 4.0  ns 
      
Blood pressure, Hg mm (mean ± SD) 
Systolic 133 ± 18  130 ± 18  ns 
Diastolic 87 ± 13  82 ± 11  ns 
      
Ever diagnosed with high cholesterol level 
Yes 47 56 764 17 <0.0001 
No 31 37 3296 75  
Do not know 6 7 361 8  
      
Cholesterol-lowering drug usage 
Yes 12 14 218 5 <0.0001 
No 72 86 4205 95  
      
Diabetes 
Yes 5c 6 107 2 ns 
No 78 94 4314 98  
      
Stroke or MI 
Yes 4 5 152 3 ns 
No 80 95 4269 97  
      
Dietary fat intake (en% fat) 
30 22 26 508 11 <0.0001 
>30 62 74 3913 89  
      
Activity patternd 
Low 35 42 1839 42 ns 
High 49 58 2582 58  
Baseline total blood cholesterol, mmol/l (mean ± SD)e 6.2 ± 1.0  5.5 ± 1.0  <0.0001 
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a
 Numbers vary due to missing values. 
b
 
2
-test or t-test. 
c
 Of which two persons reported to have type I diabetes. 
d
 Low = less than 3.5 h/week moderate or strenuous activity, high = more than 3.5 h/week 
moderate or strenuous activity. 
e
 Values obtained from 1994 to 1998.  
When we compared the four groups: i.e. enriched margarine users, cholesterol-lowering drug 
users, combination users and non-users, it appeared that a high fat intake was less prevalent 
among the combination users (50% ate more than 30 en% fat), compared to the total non-
users (Table 2). In the combination group and the cholesterol-lowering drug using group, all 
subjects were ever diagnosed with a high cholesterol level. Among the enriched margarine 
users this was the case for 49%, and among the total non-using group 13% was ever 
diagnosed with high cholesterol level.  
Table 2.  
Characteristics of phytosterol/-stanol enriched margarine users, cholesterol-lowering drug 
users, combination users and non-users, in a Dutch cohort (n = 4505)a  
 
Enriched 
margarine 
users (n = 72) 
n (%) 
Cholesterol-
lowering drug 
users (n = 218) n 
(%) 
Combination 
users (n = 12) 
n (%) 
Non-users 
(n = 4203) n 
(%) 
Age, yrs (mean ± SD) 53.6 ± 8.8a 59.5 ± 8.1b 53.9 ± 6.8 50.8 ± 10.2a 
Ever diagnosed with high cholesterol level 35 (49%)a 218 (100%)b 12 (100%)b 546 (13%)c 
     
Stroke or MI 
Yes 0 (0%)a 68 (31%)b 4 (33%)b 84 (2%)a 
No 72 (100%) 150 (69%) 8 (67%) 4119 (98%) 
     
Dietary fat intake (en% fat) 
30 16 (22%)a 46 (21%)a 6 (50%)b 462 (11%)c 
>30 56 (78%) 172 (79%) 6 (50%) 3741 (89%) 
Only those values that are significantly different are presented.  
Different superscripts (a, b or c) represent statistically significantly differences (p < 0.05) 
among the groups. 
The non-using group had a significantly lower baseline total blood cholesterol level compared 
to the other groups (Table 3). Mean spontaneous daily use for phytosterol-eniched margarine 
was 15 ± 8 g, ranging from 0.6 to 38 g (n = 71), and for phyostanol-enriched margarine was 
9 ± 6 g, ranging from 0.5 to 21 g (n = 13). Of the 84 users, 81% ate less than the 
recommended 20 g/d. Men used significantly more of the enriched margarine than women 
(16 ± 9 g/d vs. 12 ± 7 g/d, p = 0.01). Between the group of enriched margarine users and the 
combination users there was no significant difference in the mean consumption levels of 
margarine (14 ± 8 g/d vs. 14 ± 9 g/d).  
Food and Chemical Toxicology Volume 44, Issue 10 , October 2006, Pages 1682-1688  
Table 3.  
Baseline data and change in levels upon re-examination of total blood cholesterol, HDL 
cholesterol, and total blood cholesterol/HDL ratio in phytosterol/-stanol enriched margarine 
users, cholesterol lowering drug users, combination users and non-users in a Dutch cohort 
(n = 4505)a  
 
Enriched 
margarine users 
(n = 72) 
mean ± SD 
Cholesterol-
lowering drug 
users (n = 218) 
mean ± SD 
Combination 
users (n = 12) 
mean ± SD 
Non-users 
(n = 4203) 
mean ± SD 
Total blood cholesterol (mmol/l) 
Baseline 6.25 ± 0.97 6.51 ± 1.35 6.07 ± 0.90 5.44 ± 0.98a 
5 yrs difference −0.08 ± 0.83a −1.17 ± 1.34b −1.34 ± 0.78b 0.26 ± 0.71c 
Change  −10% (% of group) 26%a 64%b 83%b 10%c 
     
HDL cholesterol (mmol/l) 
Baseline 1.41 ± 0.38a 1.19 ± 0.30b 1.17 ± 0.24a,b 1.39 ± 0.38a 
5 yrs difference −0.00 ± 0.18 0.03 ± 0.21 0.05 ± 0.26 −0.01 ± 0.23 
     
Total/HDL ratio (mmol/l) 
Baseline 4.8 ± 1.63a 5.8 ± 1.91b 5.31 ± 0.95a,b,c 4.20 ± 1.48c 
5 yrs difference −0.09 ± 1.03a −1.15 ± 1. 67b −1.15 ± 0.91b 0.26 ± 1.03c 
Different superscripts (a, b or c) represent statistically significantly differences (p < 0.05) 
among the groups. 
At re-examination, i.e. during the period of consumption of margarines enriched with 
phytosterols and phytostanols, total blood cholesterol in the enriched margarine users had on 
average decreased with 0.08 mmol/l, although this decrease was not significant (p = 0.41). In 
contrast, total blood cholesterol had significantly (p < 0.0001) increased with 0.26 mmol/l in 
the total group of non-users. The cholesterol-lowering drug users and combination users had 
a significant (p < 0.0001) decrease in total blood cholesterol of 1.17 mmol/l and 1.34 mmol/l 
respectively. A similar effect was found for the total blood cholesterol/HDL ratio. In Table 3, 
the overall results of the statistical tests among the four groups are presented, whereas in Fig. 
1, results are visualised for the change in total blood cholesterol over time.  
 
Fig. 1. Baseline data ( ) and data upon re-examination () of total blood cholesterol levels in 
phytosterol/-stanol enriched margarine users, cholesterol-lowering drug users, combination 
users and non-users in a Dutch cohort (n = 4505). (Statistically significant over time: 
**p < 0.05, ***p < 0.001.)  
Food and Chemical Toxicology Volume 44, Issue 10 , October 2006, Pages 1682-1688  
There was no significant change in blood HDL cholesterol concentration in each of the four 
groups. Between men and women, there was no significant difference in five years change in 
blood cholesterol level (p > 0.05).  
We calculated the amount of subjects that attained a decline in total blood cholesterol level of 
10%, because this level of decline is claimed by the producers of the phytosterol/-stanol 
enriched margarines. Of the enriched margarine users 26% achieved this. For the cholesterol 
lowering drug users and combination users this was 64% and 83% respectively. Nonetheless, 
in the non-using group there were also 10% of the subjects who showed a ‘spontaneous’ 
decline of 10% in total blood cholesterol level (Table 3).  
To further determine the effect of phytosterol/-stanol enriched margarine on the observed lipid 
changes between baseline and re-examination, gender, age, alcohol intake, fat intake, BMI, 
smoking, diabetes and the use of cholesterol-lowering drugs were entered into a multivariate 
model as covariates. Of these covariates, cholesterol lowering drug use, age, fat intake and 
BMI contributed significantly to the model. It made no difference whether we put total fat 
intake or saturated fat intake into the model (results not shown). After correction for the 
covariates and regression to the mean, the use of enriched margarine had a significant 
lowering effect on the five years change in total blood cholesterol level of −0.30 mmol/l 
compared to non-use of enriched margarine (Table 4).  
Table 4.  
The effect of phytosterol or -stanol enriched margarine use vs. non-use, and the effect of 
cholesterol-lowering drug use vs. non-use on baseline vs. re-examination in total blood 
cholesterol and HDL levels, and total blood cholesterol/HDL ratio, according to multivariate 
regression analysis  
 
Crude  
 
Adjusted  
 
 ß (95% CI) p-Value ß (95% CI) p-Value 
Total blood cholesterol 5 yrs difference (mmol/l) 
Enriched margarine −0.45 (−0.27; −0.63) <0.0001 −0.30 (−0.14; −0.47)a 0.0003 
cholesterol-lowering drugs −1.43 (−1.22; −1.53) <0.0001 −1.35 (−1.25; −1.45)b <0.0001 
     
HDL cholesterol 5 yrs difference (mmol/l) 
Enriched margarine 0.02 (0.07; −0.03) 0.50 0.01 (0.06; −0.04)a 0.66 
cholesterol-lowering drugs 0.04 (0.07; 0.01) 0.007 0.03 (0.06; 0.00) b 0.04 
     
Total/HDL ratio 5 yrs difference (mmol/l) 
Enriched margarine −0.43 (−0.19; −0.68) 0.0004 −0.29 -(0.06; −0.52)a 0.02 
cholesterol-lowering drugs −1.40 (−1.26; −1.55) <0.0001 −1.31 (−1.17; −1.46)b <0.0001 
a
 Adjusted for age, cholesterol-lowering drug use, fat intake and BMI. 
b
 Adjusted for age, phytosterol/-stanol enriched margarine use, fat intake and BMI.  
4. Discussion 
Blood cholesterol levels remained stable over a period of five years in users of phytosterol 
and -stanol enriched margarines whereas it increased in non-users. After correction for 
covariates and regression to the mean, the mean difference in total blood cholesterol levels 
between users and non-users of the enriched margarine was 0.30 mmol/l (95% CI: 0.14; 
0.47).  
The observed increase of 0.26 mmol/l in total blood cholesterol levels of non-users can at 
least be explained partly by an aging effect as people have turned five years older upon re-
examination. It seems therefore that the longer term beneficial health effect of the enriched 
margarine, used under free-living conditions can be ascribed to a stabilization of the 
cholesterol level over a longer time period, in contrast with an increase of about 5% in non-
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users. Another potential reason for the increase observed in the total cholesterol levels in the 
non-using group may be an increase in BMI: i.e. 0.7 kg/m2 over five years time.  
The reported average daily consumption of 14 g enriched margarine under free-living 
conditions is lower than the amount of 20 g per day recommended by the producers of the 
enriched margarines. Only one in five users of the phytosterol or -stanol enriched margarines 
ate the recommended amount of 20 g of margarine per day or more. Also in a Finnish 
population it was shown that the use of enriched margarine is often inconsistent (Luoto et al., 
2004). This limited consumed amount may have diminished the blood cholesterol-lowering 
effect of the phytosterol or -stanol enriched margarine. But, given the low average intake of 
approximately 1.3 g plant sterols per day (14 g margarine), the eventual size of the 
beneficial effect on total blood cholesterol is comparable to what has been found in clinical 
settings. For example, Hendriks et al. (2003) found a decrease in total blood cholesterol of 
0.31 mmol/l (95% CI: 0.20; 0.41) over a one year period, with a relatively low intake of plant 
sterols of 1.6 g/d.  
The free-living conditions of this study have the advantage that results are a representation of 
what is happening in daily practice and therefore relevant for public health. The disadvantage 
is that confounding by other factors cannot be excluded. For instance, there was a difference 
in knowledge about high cholesterol level between users and non-users (56% vs. 18%) and a 
difference in the amount of en% fat intake. Users of the enriched margarine, especially the 
combination users ate considerably less fat than non-users. This could indicate that the blood 
cholesterol level of the users had more declined compared to that of non-users, because 
users of the enriched margarine act upon the knowledge of having an elevated cholesterol 
level. This implicates that we might slightly overestimate the sole effect of phytosterol/-stanol 
enriched margarine consumption and thus present the maximum achieved effect. Although 
we adjusted for the intake of fat and other factors that influence blood cholesterol, we can not 
exclude some persisting residual confounding.  
In our study population, cholesterol-lowering drug use was more important than the use of 
margarine enriched with plant sterols/-stanols for a decrease in blood cholesterol level. In 
total 26% of the enriched margarine users achieved the intended result of a 10% decrease in 
total blood cholesterol concentration, while this was the case for 64% of those subjects who 
used cholesterol-lowering drugs. In this study, 12 subjects used both enriched margarine and 
cholesterol-lowering drugs. A combination of cholesterol-lowering drug therapy with a 
phytosterol regimen has been the topic of recent intervention trials. Most studies found an 
additive effect of phytosterols and -stanols on cholesterol lowering drugs (Blair et al., 2000, 
Simons, 2002 and Katan et al., 2003), but not all (Neil et al., 2001). Although our results 
showed a trend towards an additive effect, the group of subjects that used both enriched 
margarine and cholesterol-lowering drugs was too small (n = 12) to have enough power to 
demonstrate a significant effect. In contrast to this potential beneficial result of a combination 
therapy there has also been some concern about a potential atherosclerotic and thus 
negative effect of phytosterol consumption especially when combined with statins (Patel and 
Thompson, 2006) Further research should elaborate on this issue. As we wrote in the 
introduction PLM should report on effectiveness of foods in addition to (un)known adverse 
effects. This paper focused on effectiveness but did not investigate any side effects of 
phytosterol/-stanol enriched margarine use. Unfortunately, we did not have sufficient power 
and sufficiently tailored data to perform a complete PLM. Data linkage will be necessary for 
doing so.  
In free-living conditions, the amounts consumed is lower than the recommended intake. 
Subsequently, the net effect of the phytosterol and -stanol enriched margarine is less than in 
most clinical trials. At this level of use, over a five years period, the maximum effect achieved 
was a stabilisation of the cholesterol level rather than the slight increase that is usually seen 
with aging. Although this effect seems to be modest, it can still reduce the risk of coronary 
heart disease and thereby result in health benefits in the general population.  
To our knowledge, this study is the first to present achieved effects of customary phytosterol 
and -stanol enriched margarine use. As such this confirms to the extensive database on 
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efficacy of these in controlled clinical trials. This aspect of post launch monitoring is an 
important addition to the other aspects of post launch monitoring (notification, analysis and 
evaluation of potential side effects of a specific product, and investigation of consumption 
patterns) and could be extended to other functional foods and functional food ingredients.  
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